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Autoimmune thyroid diseases (AITDs), including Graves’ disease (GD) and Hashimoto’s thyroiditis (HT), are caused by immune
response to self-thyroid antigens and aﬀect approximately 2–5% of the general population. Genetic susceptibility in combination
with external factors, such as smoking, viral/bacterial infection, and chemicals, is believed to initiate the autoimmune response
against thyroid antigens. Abundant epidemiological data, including family and twin studies, point to a strong genetic inﬂuence
on the development of AITDs. Various techniques have been employed to identify genes contributing to the etiology of AITDs,
includingcandidategeneanalysisandwholegenomescreening.Thesestudieshaveenabledtheidentiﬁcationofseveralloci(genetic
regions) that are linked toAITDs,and,in someof these loci, putative AITDsusceptibility genes have been identiﬁed. Some of these
genes/loci are unique to GD and HT and some are common to both diseases, indicating that there is a shared genetic susceptibility
to GD and HT. Known AITD-susceptibility genes are classiﬁed into three groups: HLA genes, non-HLA immune-regulatory genes
(e.g., CTLA-4, PTPN22, and CD40), and thyroid-speciﬁc genes (e.g., TSHR and Tg). In this paper, we will summarize the latest
ﬁndings on AITD susceptibility genes in Japanese.
1.Introduction
Autoimmunethyroiddiseases(AITDs)arecommonautoim-
mune endocrine diseases [1], and according to one study,
AITD are the commonest autoimmune diseases in the USA
[2]. Even though the hallmark of AITD is inﬁltration of the
thyroid with thyroid reactive lymphocytes, the end result is
two clinically opposing syndromes: Hashimoto’s thyroiditis
(HT) manifesting by hypothyroidism and Graves’ disease
(GD) manifesting by hyperthyroidism. In HT, the lympho-
cytic inﬁltration of the thyroid gland leads to apoptosis of
thyroid cells and hypothyroidism [3]. In contrast, in GD, the
lymphocytic inﬁltration of the thyroid leads to activation of
TSH-receptor- (TSHR) reactive B cells that secrete TSHR-
stimulating antibodies causing hyperthyroidism [4]. GD and
HT are complex diseases, and their etiology involves both
genetic and environmental inﬂuences [1]. Up until 15 years
ago,theonlyknowngeneforAITDwasHLA-DR3haplotype
(DRB1∗03-DQB1∗02-DQA1∗0501) in Caucasians. How-
ever, with the advent of new genomic tools and the comple-
tion of the human genome and the HapMap projects, new
non-HLA genes have been identiﬁed and their functional
eﬀects on disease aetiology started to be dissected as well.
This paper will summarize the recent advances in our
understanding of the genetic contributions to the etiology of
AITD in Japanese population. Since most of the studies were
performed in relatively small size samples recruited from
Japanese population, the results have some limitations.
2. A Brief Overview of AITD Genes
Identiﬁed inCaucasians
In Caucasians, the ﬁrst locus shown to be associated with
AITDs was the HLA-DRB1 locus (reviewed in [5]). HLA-
DR3 (DRB1∗03) haplotype has been consistently shown to
be associated with GD, with an odds ratio (OR) of 2.0–3.0
[6–8]. The literature regarding HT is less consistent with
reports of associations with DR3 and DR4 in Caucasians, as
well as a negative association with DR 1 and 8, suggesting a
protective role [9]. Recently, Zeitlin et al. [10]i n v e s t i g a t e d
DRB1-DQB1-DQA1 in the largest UK Caucasian HT case
control cohort to date comprising 640 HT patients and 621
controls. A strong association between HT and DR42 Autoimmune Diseases
haplotype (DRB1∗04-DQB1∗03-DQA1∗03) was detected,
and protective eﬀects were detected for DR13 haplotype
(DRB1∗13-DQB1∗06-DQA1∗01) and DR7 [10]. It was
recently shown that arginine at position 74 of the DRβ1
chain(DRβ1-Arg74)isimportantforthedevelopmentofGD
in a signiﬁcant proportion of patients [11, 12]. A study from
England provided evidence of a primary association of HLA-
C, and, to a lesser extent HLA-B, with GD. Other genes
have also been shown to inﬂuence the expression of GD in
Caucasians [13]. These include the genes for cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4) [14, 15], CD40
[16], protein tyrosine phosphatase-22 (PTPN22) [17], thy-
roglobulin (Tg) [18, 19], and TSH-receptor (TSHR) genes
[20].
3. HLAGenesinJapanese
Located on chromosome 6p21 is the major histocompatibil-
ity complex region that encodes for HLA glycoproteins. The
HLA region is a highly polymorphic region that contains
many immune response genes and has been found to be
associated with various autoimmune disorders. The HLA
moleculebindsapeptideantigen(autoantigeninthecauseof
autoimmunity).Itpresentstheantigenforrecognitionbythe
T-cell and as such the T-cell then determines if the antigen is
self(andnoimmuneresponseismounted)ornonselfandan
immune response is mounted [21].
The HLA associations are with diﬀerent alleles in Japa-
nese. In previous studies, HLA-B35 is associated with GD
and HLA-DRw53 with HT in the Japanese population (re-
viewed in [22]). HLA-Bw46 is associated with GD and
HLA-DR9 with HT in the Chinese population (reviewed in
[22]). The European GD-associated HLA haplotype (HLA-
B∗08-DRB1∗03-DQA1∗0501-DQB1∗02) is virtually absent
in Japanese [23]. Dong et al. previously reported that HLA-
A∗02 and DPB1∗0501 are associated with Japanese GD
[24]. Recently, they also demonstrated that HLA-A∗02 and
DPB1∗0202 showed association with thyroid-stimulating
hormone-binding inhibitory immunoglobulins- (TBII) neg-
ative GD, indicating that TBII-negative GD may be geneti-
cally distinct from TBII-positive GD [25]. In addition, Wan
etal.reportedthatHLA-A∗02andDPB4∗0101areassociated
with Japanese HT [26].
4.Non-HLA Immune-Regulatory Genes
inJapanese
4.1. The CTLA-4 Gene. The cytotoxic T-lymphocyte-asso-
ciated protein 4, CTLA-4, gene is located on chromosome
2q. It is a highly polymorphic gene that was ﬁrst discovered
to be associated with risk for AITD by the candidate gene
approach. Under normal circumstances, the CTLA-4 protein
actstosuppressT-cellactivationduringnormalimmuneres-
ponse in order to prevent T-cell overactivity [27].
CD4+CD25-T-cells only express CTLA-4 on their surface
after the T-cell receptor is activated, and its engagement
with its ligand suppresses the ongoing immune response.
Decreased or absent CTLA-4 activity permits uninhibited
T-cell activity and a prolonged, unregulated immune res-
ponse [28], making CTLA-4 an attractive candidate gene for
autoimmunity. Indeed, the CTLA-4 gene has been found to
be associated with many other autoimmune diseases.
A microsatellite in 3 U T Ro fC T L A - 4h a sb e e nl i n k e dt o
AITD in Caucasians (reviewed in [27]); the longer the AT
repeat at this site is, the less inhibitory activity CTLA-4 has.
IthasalsobeenassociatedwithAITDinJapanese[29].Other
variants of CTLA-4 gene have been linked to AITD in
Caucasians (reviewed in [27]); a G allele substitution at
an A/G single nucleotide polymorphism (SNP) at position
49 was also found to be associated with AITD in Japanese
[30]. Recently, an A/G SNP downstream from the 3 UTR,
designated CT60, was found to be associated with GD in
Caucasians and has been suggested as the causative variant,
albeit this has not been conclusively demonstrated [15]. It
was also found to be associated with AITD in Japanese
[31, 32]. Interestingly, another SNP (rs231779) is more likely
the susceptibility variant for GD in Chinese Han population,
suggestingthatthesusceptibilityvariantsoftheCTLA-4gene
varied between the diﬀerent geographic populations with
GD [33]. Additionally, most recent stratiﬁcation analyses
suggested a possible synergistic interaction of CTLA-4 CT60
with HLA-A∗02 and -DPB1∗0501 in the susceptibility to
TBII-positive GD [34].
4.2. The CD40 Gene. The CD40 molecule, located on chro-
mosome 20q, is crucial to both innate adaptive immune res-
ponses. It is present on the surface of antigen presenting cells
(APCs) including B cells. The T-cell-APC interaction results
in activation of CD40 as a costimulatory molecule. CD40
also plays a critical role in activating B lymphocytes allowing
them to terminally diﬀerentiate and secrete antibodies (re-
viewed in [35]). It is no surprise that the CD40 gene has
been linked to many autoimmune disorders. Whole genome
linkage scanning has identiﬁed strong linkage of CD40 to
GD. The causative variant predisposing to GD is a C/T poly-
morphism in the Kozak sequence (dbSNP accession number
rs1883832), a nucleotide sequence that is essential for the
initiation of translation of the CD40 molecule. Speciﬁcally,
the CC genotype has been identiﬁed in Caucasians to be
associated with GD [16]. Indeed, functional studies demon-
strated that the C-allele of this SNP increased CD40 mRNA
translation by ∼20–30% when compared with the protective
Ta l l e l e[ 27]. We and others have also conﬁrmed an asso-
ciation between the rs1883832 and GD in Japanese [36, 37].
4.3. The PTPN22 Gene. The protein tyrosine phosphatase-
22 (PTPN22) gene encodes for the lymphoid tyrosine phos-
phatase (LYP), a molecule that, similar to CTLA-4, functions
to inhibit T-cell activation [38]. A nonsynonymous SNP in
the PTPN22 gene, R620W (dbSNP accession number
rs2476601), was found to be associated with GD, as well as
other autoimmune diseases. This substitution results in a
functional change in the LYP protein resulting in activation
of T-cell, but the mechanism is unclear [35]. Indeed, this
association seems speciﬁc for Caucasians and was not found
in the Japanese GD population [39].Autoimmune Diseases 3
Table 1: PTPN22 haplotype structure and frequenciesa.
SNP ID Haplotype comparisonb
Haplotype 1 2 3 4 5 AITD GD HT Controls AITD versus
Controls P value
GD versus
Controls P value
HT versus
Controls P value
1 C T T G A 0.59 0.59 0.59 0.60 0.69 0.75 0.69
2 C C T G C 0.20 0.20 0.20 0.17 0.24 0.29 0.28
3 C C C A A 0.13 0.13 0.13 0.12 0.54 0.66 0.47
4 T C C G A 0.067 0.066 0.070 0.060 0.63 0.72 0.61
5 C C T G A 0.013 0.017 0.0061 0.051 <0.0001 <0.0001 0.0004
aThe program, SNPAlyze ver. 7.0 Standard, was used to estimate common (frequencies > 0.01) haplotypes for the ﬁve SNPs genotyped.
bEach haplotype was compared with the other haplotypes combined.
SNP: single nucleotide polymorphism; AITD: autoimmune thyroid disease; GD: Graves’ disease; HT: Hashimoto’s thyroiditis.
Recently, the rs2488457 SNP in the promoter region was
reported to be associated with acute onset T1D in a Japanese
population [40]. However, there was no association of the
rs2488457 SNP with GD [41]. Furthermore, the rs3789604
SNP of the PTPN22 gene was found to be associated with
RA, independently of rs2476601 [42]. The rs3789604 SNP
lies 1496 bases downstream of PTPN22 at the 50 end of
the round spermatid basic protein 1 gene (RSBN1), where
it encodes either a silent mutation or putative transcription
factor-binding sites (TRBS), depending on the transcript.
Recently, the AA-genotype and A-allele frequencies of the
rs3789604 were signiﬁcantly higher in GD patients than in
control subjects [43], suggesting that the rs3789604 or a gene
with linkage disequilibrium may be relevant to susceptibility
to GD in Japanese populations. Therefore, we further anal-
yzed ﬁve other SNPs including rs12760457, rs2797415,
rs1310182, rs2476599, and rs3789604, to clarify whether
a susceptibility locus for AITD exists at another location
within the PTPN22 gene. Our results showed no association
with disease of any of the individual SNPs [44].
Because of the strong LD between ﬁve variants, haplo-
type analysis was undertaken using the computer program
SNPAlyze version 7.0. Five haplotypes were identiﬁed, three
of which (haplotypes 1, 2, and 4) were correlated with hap-
lotypes 1, 4, and 5 identiﬁed in the report by Carlton et al.
(Table 1)[ 42]. Four haplotypes (haplotypes 1–4) were rela-
tivelycommon,and1haplotypewasrare.Distributionofthe
haplotype is signiﬁcantly diﬀerent between AITD and con-
trol by permutation procedure (P = 0.0036) [44]. A novel
protective eﬀect of a haplotype containing ﬁve SNPs was ob-
served (P<0.0001 for AITD, P<0.0001 for GD, and
P<0.0001 for HT, resp.) (Table 1)[ 44].
4.4. The Zinc-Finger Gene in the AITD Susceptibility Region
(ZFAT) Gene. Shirasawa et al. [45] identiﬁed a novel zinc-
ﬁnger gene, designated ZFAT, as one of the AITD susceptibil-
ity genes in 8q23-q24 through an initial association analysis
using the probands in their previous linkage analysis [46].
The distance between thyroglobulin and ZFAT genes is about
1.8Mbp. A subsequent association analysis of the samples
from a total of 515 aﬀected individuals and 526 controls in
Japanese [45]. The T allele of the SNP located in the intron 9
of ZFAT (Ex9b-SNP10) is associated with increased risk for
AITDs (dominant model: OR = 1.7, P = 9.1 × 10
−5)[ 45].
TheEx9b-SNP10islocatedinthe3 -UTRoftruncated-ZFAT
(TR-ZFAT) and the promoter region of the SAS-ZFAT [45].
The human ZFAT gene encodes a 1,243-amino acid residue
protein containing one AT-hook and 18 C2H2 zinc-ﬁnger
domains. ZFAT is also highly conserved among species from
ﬁsh to human [44]. The ZFAT protein is expressed in the B
and T lymphocytes in mice, and ZFAT regulates the genes
involved in immune responses [47]. Furthermore, ZFAT is
an anti-apoptotic molecule that is critical for cell survival in
human leukemic MOLT-4 cells [48].
4.5. The FCRL Genes. Fc receptor-like 3 (FCRL3) is one of
ﬁve FCRL genes that are preferentially expressed on B lym-
phocytes and have a highly structural homology with Fc
receptors [49]. The 1p21-23 cytoband, in which the FCRL
family resides, has been identiﬁed as a candidate locus for
multiple autoimmune disorders in both human and murine
models [50]. Kochi et al. [51] identiﬁed a strong association
of SNPs in this region with GD susceptibility in Japanese
and concluded that the origin of the association was a regu-
latory SNP in the promoter region of FCRL3. This suscep-
tibility gene of GD was ﬁrst identiﬁed from Japanese popu-
lation. This SNP (−169C/T) (dbSNP accession number
rs7522061) alters the binding aﬃnity of NFκB and regulates
gene expression, and high FCRL3 expression on B lympho-
cytes is observed in individuals with the disease-susceptible
genotype.TheSNPrs7522061intheFCRL3genewasalsore-
ported to be associated with AITD in Caucasians [52]a n d
two other autoimmune diseases, rheumatoid arthritis (RA),
and systemic lupus erythematosus (SLE) [51]. More recently,
SNP rs3761959, which tags rs7522061 and rs7528684 (previ-
ouslyassociatedwithRAandGD),wasassociatedwithGDin
the extended cohort, conﬁrming the original result. In total,
three of the seven FCRL3 SNPs showed some evidence for
association (P<0.05), with SNP rs11264798 showing the
strongest association of the tag SNPs (P = 4.0 × 10
−3)[ 53].
SNP rs6667109 in FCRL5, which tagged SNPs rs6427384,
rs2012199, and rs6679793, all found to be weakly associated
in the original study, showed little evidence of association in
the extended cohort [53].
4.6. Other Immune-Regulatory Genes. Other immune-regul-
atory genes tested for association with AITD in Japanese4 Autoimmune Diseases
include Interleukin-23 receptor (IL-23R) [54], Interferon-
induced helicase (IFIH1) [55], FOXP3 [56], and interleukin-
2 receptor alpha (IL-2RA) genes [44].
Interleukin-23 (IL-23) is a recently discovered hetero-
dimeric cytokine. IL-23 acts primarily on CD4+ T cells that
have already been exposed to antigens, sustaining long-term
cellular immunity by promoting survival and the eﬀector
cytokine production of T helper 1 (Th1) memory cells [57].
Several SNPs in the IL-23R gene have recently been shown
to be associated with autoimmune and inﬂammatory condi-
tions, including Crohn’s disease [58], rheumatoid arthri-
tis (RA) [59], and psoriasis [60]. More recently, an associa-
tion was reported between these SNPs and GD and Graves’
ophthalmopathy (GO) in North American Caucasians [61].
SNP rs11209026 is speciﬁc for Crohn’s disease [58], while
rs10889677 and rs2201841 have been shown to confer risk
for both Crohn’s disease [58] and rheumatoid arthritis (RA)
[59]. Intriguingly, these latter two SNPs are the same SNPs
Huber et al. [61] found to be associated with GO; however,
rs7530511 was associated with GD, but not speciﬁcally with
GO [61]. In contrast, the rs11209026 SNP did not show an
association with GD or GO in their cohort [61], but this
SNP has not been proven to be the causative SNP in Crohn’s
disease [58]. Thus, diﬀerent variants in the IL-23R gene may
predispose individuals to diﬀerent autoimmune conditions.
We did not ﬁnd an association between the IL-23R gene and
AITDs in the Japanese population, perhaps due to ethnic
diﬀerences, environmental factors, or a very small eﬀect that
cannot be detected in our dataset [54].
Interferon-induced helicase 1 (IFIH1) is thought to have
a role in protecting the host from viral infection by sensing
viral nucleic acids in the cytoplasm and triggering a cellular
antiviral and apoptotic response [62, 63]. Because Coxsackie
and other enteroviral infections are epidemiologically linked
to type 1 diabetes (T1D) incidence [64], it was suggested that
IFIH1 polymorphism acts as a molecular link between the
speciﬁc viral trigger and the autoimmune response in T1D
[65]. Recently, using preliminary results from large-scale
association analyses of nonsynonymous SNPs, a novel locus
for T1D was identiﬁed; IFIH1, which is also known as the
melanoma a diﬀerentiation-associated 5 (MDA-5), or Heli-
card, gene [65]. Using logistic regression analysis, the most
strongly associated marker in IFIH1 was identiﬁed as SNP
rs1990760, which encodes an alanine to threonine amino
acid change at codon 946, with an odds ratio for association
with T1D of 1.16 (5%–95% conﬁdence interval, 1.11–1.22)
for the major allele [65]. More recently, the association
of IFIH1 alleles with GD in Caucasians was found to be
stronger than that with T1D, with an OR for association of
1.47, in contrast to the 1.16 seen for T1D [66]. However,
this was not found when IFIH1 was also investigated in a
largerindependentGDdataset[67].TheIFIH1geneencodes
transcripts that have widespread expression in lymphoid and
other tissues, thus suggesting that they could have a role
in numerous autoimmune conditions. However, our data
did not show signiﬁcant diﬀerences in allele or genotype
frequencies for the rs1990760 SNP between AITD patients
and control subjects in Japanese [55].
Two whole genome scans for linkage in GD have shown
evidence for linkage at putative X-chromosome loci, Xq21
[68], and Xp11 [69], and these loci have also been identiﬁed
in localized linkage scans of the X-chromosome, Xq21 [68]
and Xp11 [70], although one of the two genome wide screen
increased their numbers and performed an enlarged genome
wide screen and no evidence for Xp21 as a region of linkage
to GD [71]. In terms of broader relevancy to autoimmunity
in general, Xp11 has also been linked to other autoimmune
disorders, T1D, multiple sclerosis, and RA, thus suggesting
the presence of common susceptibility polymorphism(s)
[72–74]. The FOXP3 gene is located at Xp11.23 within this
area of autoimmune disease linkage and is therefore an
excellent positional candidate gene for autoimmunity at this
locus. Indeed, Bassuny et al. [75] reported an association
between a functional microsatellite polymorphism, (GT)n,
locatedinthepromoter/enhancerregionofFOXP3,andT1D
in a Japanese population. However, a subsequent study could
not conﬁrm the FOXP3 association with T1D in an Italian
population [76]. A recent study from the UK tested several
FOXP3 polymorphisms for associations with GD and found
no robust evidence that those polymorphisms contributes
to the susceptibility to GD [77]. We tested the FOXP3 gene
locus for associations with AITDs in two cohorts of US Cau-
casians and Japanese AITD patients [56]. Our study demon-
strated a weak association between polymorphisms of the
FOXP3 gene and AITD in US Caucasians but not in the Japa-
nese. However, one group from Japanese reported that the
−3279A/C SNP of the FOXP3 gene is related to the develop-
ment and intractability of GD and the −2383CC genotype
to the severity of HT [78]. These results, if replicated, may
suggest that inherited abnormalities of Treg function may
contribute to the etiology of AITD.
The interleukin-2 receptor-α (IL-2RA) encodes the α-
chain of the IL-2 receptor (IL-2R) complex (also known as
CD25), which is central to immune regulation as an impor-
tant modulator of self-tolerance and immunity [79], and the
IL-2RAassociationwithtype1diabeteswasoriginallyidenti-
ﬁed by Vella and coworkers [80] .T h eI L - 2 R Ag e n eh a sa l s o
beenassociatedwithGD[81],RA[82],andmultiplesclerosis
[83] in Caucasians, which implies that this locus may have
a general eﬀect on predisposition to autoimmunity. Recently,
two SNPs in intron 1 of the IL-2RA, rs706778, and
rs3118470, were associated with T1D in the Japanese popu-
lation [84]. However, we did not ﬁnd an association between
the IL-2RA gene and AITDs in the Japanese population [44].
It may be due to the eﬀect size being smaller than that seen in
Caucasiansorthattheredatasetmaynotbepowerfulenough
to detect such an eﬀect.
5. Thyroid-Speciﬁc GenesinJapanese
5.1.TheThyroglobulinGene. Thethyroglobulin(Tg)protein
is the major thyroidal protein antigen and is a precursor to
thyroid hormones. Tg is also a key antigen in AITD as evi-
denced by the fact HT is characterized by antithyroglobulin
antibodies whicharedetectedin75%ofpatients[35].Whole
genome linkage studies identiﬁed a locus on chromosomeAutoimmune Diseases 5
8q24 that was linked with AITD; this locus contained the Tg
gene [71]. Sequencing of the Tg gene identiﬁed several non-
synonymous SNPs that were associated with AITD [85]. In
our dataset of Japanese AITD patients we found an associa-
tionbetweenaTgmicrosatellitepolymorphismandHT[86].
5.2. TSH Receptor (TSHR) Gene. T h eT S H Rg e n ei sl o c a t e d
on chromosome 14q. It was found to be associated with GD
both by the candidate gene approach and by whole genome
linkage studies [71]. The TSHR gene was a prime candi-
date gene for GD since GD is caused by autoantibodies that
bind to and stimulate the TSH-receptor. Several TSHR
SNPs have been tested for association with GD, including
nonsynonymous SNPs in the extracellular TSH-receptor
domain and in the intracellular domain of the TSHR; all of
these gave conﬂicting results [87]. However, linkage studies
demonstrated signiﬁcant evidence for linkage of GD with a
locus on chromosome 14q harbouring the TSHR gene and
many other genes [71]. It was later found that noncoding
SNPs in intron 1 of the TSHR confer the association with
GD [88]. Recently, association within the TSHR intron 1
in Caucasians was narrowed down to two SNPs (rs179247
andrs12101255)withinintron1[89].Thedisease-associated
genotypes of rs179247 (AA) and rs12101255 (TT) showed
reduced mRNA expression ratios of ﬂTSHR relative to two
alternate TSHR mRNA splice variants [89]. Płoski et al. [90]
validated association of TSHR intron 1 SNPs with GD in
three independent European cohorts and demonstrated that
the etiological variant within the TSHR is likely to be in
strong linkage disequilibrium with rs12101255. In Japanese,
multipleSNPsinintron7ofTSHRgenewereassociatedwith
GD [91].
6. Conclusions andFutureDirection
Through the genetic studies undertaken to date, we now
knowthatsubstantialethnicdiﬀerencesexistinAITDgenetic
predisposition between populations of Caucasian and Japa-
nese ancestries. Beside the HLA-DRB1 alleles as described,
the most evident ethnic diﬀerence is seen in the nonsyn-
onymous coding polymorphism of the PTPN22 gene in
Caucasian populations. This polymorphism is rarely found
in Japanese population [39] and thus speciﬁcally contributes
toAITDin populations ofCaucasiandescent.Theabsenceof
adisease-riskalleleinapopulation,asinthecaseofPTPN22,
can easily explain the genetic heterogeneity between pop-
ulations [92]. However, the situation is more complex in
cases where the disease-risk allele is shared among diﬀerent
populations and the results of association tests are not. This
could occur when (1) a positive association in the primary
report represents a false positive due to sampling biases, (2)
a negative association observed in a replication study is a
false negative due to a lack of statistical power, or (3) true
genetic heterogeneity exists (genetic contribution of the gene
polymorphisms is zero in a population, or lower than that of
the population originally reported) [92].
The most recent step in the evolution of genetic studies
in common disease sees association analysis performed at
a genome-wide level to produce genome-wide association
studies [93–95]. These studies, now beginning to emerge in
some common diseases, bring together the latest advances in
our genetic maps, large-scale automated genotyping techno-
logies, and large national DNA collections [96–98]. Geno-
typing technology is now being utilized which is able to pro-
duceinformationonover500000SNPsincohortsofbetween
2000 and 3000 samples. These studies will not only help
identify novel loci but should also provide insights into
the diﬀerent technical, analytical, methodological, and bio-
logical aspects of genome-wide association analysis. Assum-
ing that these new approaches deliver some novel loci, an
important next step will be the validation and replication
of loci that will then justify more detailed ﬁne mapping
and functional analyses. Recently, one group from China
did the ﬁrst >500k published SNP screen in a large Chinese
population [99]. They identiﬁed two new susceptibility loci
for atopic dermatitis in the Chinese Han population [99].
Since genetic heterogeneity of disease susceptibility variants
between ethnic groups is common in complex diseases,
following up this work will be important in the future.
Genetic analyses undertaken in the last decade have re-
vealed a completely new picture of AITD pathogenesis and
made us aware of heterogeneity among individuals and
populations. Our ﬁnal goal is to establish new treatments
for AITD, based on the pathogenesis and prognosis of
individuals, which could lead to the development of tailor-
made therapies for AITD. To reach this goal, we should con-
tinue to uncover unknown genetic predispositions and clari-
fy diﬀerences in roles among ethnicities. Upcoming genome-
wide scans for additional populations worldwide and the
meta-analysis of these studies may elucidate the complete
picture of AITD.
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